The Kidney Institute is a world-class, internationally recognized research center. Our mission is to support basic, clinical and translational research leading to major advances in the prevention and treatment of kidney diseases. The Kidney Institute is committed to the pursuit of excellence by creating an environment that empowers creativity and innovation, and encourages collaboration and teamwork between laboratory scientists and physicians.
As one of the top kidney research centers in the country, the Kidney Institute gives hope to those with kidney disease. Our research teams identify risk factors that affect the progression of kidney disease and we develop improved treatments.
News & Highlights
FDA approves the first treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The U.S. Food and Drug Administration (FDA) approved JYNARQUETM (Tolvaptan), an arginine vasopressin (AVP) V2 receptor antagonist, as the first therapeutic treatment for patients with ADPKD in the United States. The concept for the use of AVP V2 receptor blockers to treat ADPKD originated from basic research performed in the Jared Grantham Kidney Institute at the University of Kansas Medical Center, which owns the use patent. And critical to the development of JYNARQUETM were clinical trials carried out by KUMC Kidney Institute clinical investigators.